|
||||||
 |
||||||
|
|
|
 |
|
          May 13, 2013
May 8, 2013
|
|
All prices delayed at least 15 minutes.
All prices delayed at least 20 minutes. |
|
Animal Health News ReleaseBioniche Life Sciences Inc. Keynote Speaker at 7th Annual NZBIO Conference in New Zealand
22/03/11 Presentation related to addressing the misuse of antibiotics in livestock and the role of vaccines in controlling zoonotic disease
BELLEVILLE, ON, March 21 - Bioniche Life Sciences Inc. (TSX & ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today gave a keynote presentation to attendees at the 7th annual NZBIO conference in Auckland, New Zealand. The presentation - by Chairman, President & CEO Graeme McRae - focused on addressing the inappropriate use of antibiotics in livestock and the role of vaccines in controlling zoonotic (animal-to-human transmitted) disease.
In the NZBIO presentation, Mr. McRae highlighted the fact that in the U.S. alone, an estimated 13.2 million kilograms of antibiotics are given to livestock each year (USFDA), many of which are used to treat human diseases. Some of these are given to sick animals as a disease treatment, but others are given prophylactically as a means to prevent disease and/or promote the growth of the animals. This poses a risk to human health as it can result in the emergence of "superbugs" that are resistant to antibiotics and, thus, undermine the effectiveness of antibiotics in treating human diseases.
"When I founded our Company in 1979, it was with an objective of developing non-antibiotic solutions to treat diseases of livestock," said Graeme McRae, Chairman, President & CEO of Bioniche Life Sciences Inc. "Over the years, the Company has developed a number of immune stimulant products for animals, designed to boost the animals' immune systems to fight disease naturally. This technology has been refined for the treatment of human bladder cancer, now in Phase III clinical testing. The Company is also developing vaccines as tools to prevent diseases of animals."
As an example, the Company has a vaccine in late-stage development against Rhodococcus equi (a disease that is frequently treated with human antibiotics). Rhodococcus equi is a common and debilitating respiratory disease affecting young foals that can impair their future respiratory capacity and performance potential.
The Company's marketed immune stimulant products for animals include:
Further immune stimulant therapies for animals are being explored for future development.
About NZBIO/NZBIO Conference 2011
NZBIO is a member-based organisation which acts to enable an effective environment for successful New Zealand bio enterprise. It aims to achieve this purpose through four strategic objectives:
The NZBIO annual conference is one of New Zealand's largest and most vibrant such events. Now in its seventh year, NZBIO is well established as the premier showcase for the New Zealand life sciences sector and attracts delegates from around the world and from all aspects of the life sciences industry.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs 214 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company’s primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. Bioniche has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2010. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company’s current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company’s ongoing quarterly and annual reporting.
For further information, please contact: ###
|
|
Categories:
|
Copyright 2004, Bioniche Life Sciences Inc. All rights reserved | Legal Disclaimer | Privacy Policy